Oncocyte to Participate at 32nd Annual Piper Sandler Virtual Healthcare Conference

Rhea-AI Summary

Oncocyte Corporation (NYSE American: OCX) will participate in the Piper Sandler Virtual Healthcare Conference on December 1, 2020, for 1-on-1 meetings. The company's mission is to enhance cancer care through molecular diagnostics with tools like DetermaRx, a test for early-stage lung cancer patients to identify recurrence risk, and DetermaIO, aimed at predicting immunotherapy responses. These innovations seek to improve patient outcomes by providing critical information at key decision points in cancer treatment.

News Market Reaction – OCX

+2.29%

+2.29% Session move

In the trading session that priced this news, OCX gained 2.29%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that company management will participate in the 1-on-1 meetings at the upcoming Piper Sandler Virtual Healthcare Conference on Tuesday, December 1, 2020.

About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies.

DetermaRx and DetermaIO are trademarks of Oncocyte Corporation. TheraSure is a trademark of Chronix Biomedical, Inc.

Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com

Media Contact
Cait Williamson, Ph.D.
LifeSci Communications, LLC
646-751-4366
cait@lifescicomms.com

Source: Oncocyte Corporation

 

FAQ

What is Oncocyte Corporation's stock symbol?

Oncocyte Corporation is traded under the stock symbol OCX.

When is the Piper Sandler Virtual Healthcare Conference?

The Piper Sandler Virtual Healthcare Conference will take place on December 1, 2020.

What are DetermaRx and DetermaIO?

DetermaRx is a test for early-stage lung cancer recurrence risk, while DetermaIO identifies patients likely to respond to immunotherapies.

What is the focus of Oncocyte Corporation?

Oncocyte Corporation focuses on providing molecular diagnostics to improve treatment decisions in cancer care.

What is the mission of Oncocyte Corporation?

The mission of Oncocyte Corporation is to provide actionable answers at critical decision points in cancer care to enhance patient outcomes.